IsoPlexis develops single-cell proteomics systems that reveal unique biological activity in small subsets of cells. This technology allows researchers to connect more directly to in vivo biology and develop more precise and personalized therapies, the company said.

The company's common stock began trading on the Nasdaq Global Select Market on October 8 under the ticker symbol ISO. Shares were offered by IsoPlexis, while Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink are acting as lead book-running managers for the offering.

AI drug development startups raised $2.1B in 1st half of 2021
The market for artificial intelligence (AI) in drug development and discovery has been red-hot in recent years. The potential impact that AI can offer...

IsoPlexis acquires sequencing methodology IP
IsoPlexis has acquired an intellectual property (IP) portfolio of 86 patents related to DNA and RNA sequencing, which it is integrating into its single-cell...

Are biotech companies really high-risk investments?
Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that...

IsoPlexis launches new personalized lab systems
IsoPlexis has launched two new personalized lab systems, IsoSpark and IsoSpark Duo for high-throughput proteomics.

IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners...